The clinical, radiological, and histopathological features of chondromyxoid fibroma can sometimes resemble those of other benign or malignant tumors. Recently, recurrent GRM1 rearrangements have been identified in chondromyxoid fibroma, and GRM1 positivity by immunohistochemistry has emerged as a dependable surrogate marker for this molecular alteration. Phosphaturic mesenchymal tumor is a rare tumor that often exhibits overexpression of fibroblastic growth factor 23 (FGF23) through various mechanisms. In this report, we present a case of GRM1-rearranged chondromyxoid fibroma that also exhibited FGF23 expression via in situ hybridization, posing significant diagnostic challenges during workup of the initial core biopsy. We hope that this case can serve as an educational resource, shedding light on a rare diagnostic pitfall.
Tu WuCInwardsCYO’LaughlinS, et al.Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. Hum Pathol. 1998;29(5):438-446.
2.
NielsenGPKeelSBDickersinGR, et al.Chondromyxoid fibroma: a tumor showing myofibroblastic, myochondroblastic, and chondrocytic differentiation. Mod Pathol. 1999;12:514-517.
3.
WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours (Vol 3). International Agency for Research on Cancer; 2020.
4.
ZupanASalapuraVŠekoranjaDPižemJ. Subcutaneous chondromyxoid fibroma with a novel PNISR::GRM1 fusion-report of a primary soft tissue tumour without connection to an underlying bone. Virchows Arch. 2023;482(5):917-921. doi:https://doi.org/10.1007/s00428-023-03519-4
5.
ZhongJSiLGengJ, et al.Chondromyxoid fibroma-like osteosarcoma: a case series and literature review. BMC Musculoskelet Disord. 2020;21(1):53.
6.
KaoYCLeeJCHuangHY. What is new about the molecular genetics in matrix-producing soft tissue tumors? The contributions to pathogenetic understanding and diagnostic classification. Virchows Arch. 2020;476(1):121-134. doi:https://doi.org/10.1007/s00428-019-02679-6
7.
NordKHLilljebjörnHVezziF, et al.GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nat Genet. 2014;46(5):474-477. doi:https://doi.org/10.1038/ng.2927
8.
BaumhoerDAmaryFFlanaganAM. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer. 2019;58(2):88-99. doi:https://doi.org/10.1002/gcc.22699
9.
ShonWFolpeALFritchieKJ. ERG expression in chondrogenic bone and soft tissue tumours. J Clin Pathol. 2015;68(2):125-129.
10.
RomeoSDuimRAJBridgeJA, et al.Heterogeneous and complex rearrangements of chromosome arm 6q in chondromyxoid fibroma: delineation of breakpoints and analysis of candidate target genes. Am J Pathol. 2010;177(3):1365-1376.
11.
TolandAMSLamSWVarmaS, et al.GRM1 immunohistochemistry distinguishes chondromyxoid fibroma from its histologic mimics. Am J Surg Pathol. 2022;46(10):1407-1414. doi:https://doi.org/10.1097/PAS.0000000000001921
12.
El-KouriNElghoucheAChenSShipchandlerTTingJ. Sinonasal chondromyxoid fibroma: case report and literature review. Cureus. 2019;11(10):e5841. doi:https://doi.org/10.7759/cureus.5841
13.
ElsamanodyAVan den AardwegMSmitsAWillemsSTopsakalV. Chondromyxoid fibroma of the mastoid: a rare entity with comprehensive literature review. J Int Adv Otol. 2020;16(1):117-122. doi:https://doi.org/10.5152/iao.2019.6911
14.
WilsonAJKyriakosMAckermanLV. Chondromyxoid fibroma: radiographic appearance in 38 cases and in a review of the literature. Radiology. 1991;179(2):513-518. doi:https://doi.org/10.1148/radiology.179.2.2014302
15.
Campos FilhoRde CamargoOPCrociATde OliveiraNR. Chondromyxoid fibroma: a study based on 18 cases. Rev Paul Med. 1992;110(2):59-62.
16.
MeredithDMFletcherCDMJoVY. Chondromyxoid fibroma arising in craniofacial sites: a clinicopathologic analysis of 25 cases. Am J Surg Pathol. 2018;42(3):392-400. doi:https://doi.org/10.1097/PAS.0000000000001019. PMID: 29324473.
17.
BasakBHaraganAShackclothMThekkudanJ. Chondromyxoid fibroma of the rib: a rare benign tumor with potential for local recurrence. Cureus. 2021;13(10):e19172. doi:https://doi.org/10.7759/cureus.19172
18.
AgaimyAMichalMChioseaS, et al.Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic Spectrum. Am J Surg Pathol. 2017;41(10):1371-1380. doi:https://doi.org/10.1097/PAS.0000000000000890
19.
BahramiAWeissSWMontgomeryE,et al.RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009;33(9):1348-1354. doi:https://doi.org/10.1097/PAS.0b013e3181aa2311
20.
GrahamRKrishnamurthySOliveiraAInwardsCFolpeAL. Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas. J Clin Pathol. 2012;65(10):907-909. doi:https://doi.org/10.1136/jclinpath-2012-200852
21.
ShibaEMatsuyamaAShibuyaR,et al.Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol. 2016;11(1):26. doi:https://doi.org/10.1186/s13000-016-0477-3
22.
Sent-DouxKNMackinnonCLeeJCFolpeALHabeebO. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the “nonphosphaturic” variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization. Hum Pathol. 2018;80:94-98. doi:https://doi.org/10.1016/j.humpath.2018.02.022
23.
YamadaYKinoshitaIKenichiK, et al.Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant. Histopathology. 2018;72(3):460-471.
24.
ChatterjeeDBardiaAPalRSaikiaUNBhadadaSKRadotraBD. Clinical, morphological and immunohistochemical analysis of 13 cases of phosphaturic mesenchymal tumor—a holistic diagnostic approach. Ann Diagn Pathol. 2021;54:151783. doi:https://doi.org/10.1016/j.anndiagpath.2021.151783
25.
WuHBuiMMZhouLLiDZhangHZhongD. Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol. 2019;32(2):189-204.
26.
LeeJCSuSYChangouCA, et al.Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol. 2016;29(11):1335-1346. doi:https://doi.org/10.1038/modpathol.2016.137
27.
LeeCHSuSYSittampalamK, et al.Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications. Mod Pathol. 2020;33(5):858-870. doi:https://doi.org/10.1038/s41379-019-0416-4
28.
LeeJCHsiehTHKaoYC, et al.Klotho overexpression is frequently associated with upstream rearrangements in fusion-negative phosphaturic mesenchymal tumors of bone and sinonasal tract. Mod Pathol. 2023;36(12):100336. doi:https://doi.org/10.1016/j.modpat.2023.100336
LiuXYinXLiD, et al.RNA sequencing reveals novel oncogenic fusions and depicts detailed fusion transcripts of FN1-FGFR1 in phosphaturic mesenchymal tumors. Mod Pathol. 2023;36(10):100266. doi:https://doi.org/10.1016/j.modpat.2023.100266
31.
LinosKDermawanJKBaleT, et al.Expanding the molecular diversity of CIC-rearranged sarcomas with novel and very rare partners. Mod Pathol. 2023;36(5):100103. doi:https://doi.org/10.1016/j.modpat.2023.100103
32.
AmaryFBerishaFYeH, et al.H3f3a (histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41(8):1059-1068.
33.
SchaeferI-MFletcherJANielsenGP, et al.Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. 2018;126(8):552-566.
34.
AmaryMFBerishaFMozelaR, et al.The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology. 2016;69(1):121-127.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
